Post Marketing Clinical Study of Aripiprazole in Patients with Schizophrenia - Effects on Glucose Metabolism
Phase 4
- Conditions
- Schizophrenia
- Registration Number
- JPRN-jRCT1080220320
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Schizophrenic patients, who meet the F20 criteria of ICD-10, without hyperglycemia and diabetes mellitus or any history thereof
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effects on variables relating to glucose metabolism, efficacy (PANSS and CGI-I), and safety
- Secondary Outcome Measures
Name Time Method